Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. is a clinical biopharmaceutical company specializing in the discovery, development, and commercialization of drugs for cancer treatment. The company's lead product is CLR 131, a phospholipid drug conjugate (PDC) candidate currently in Phase 2 clinical studies for various cancers, including Waldenstrom's macroglobulinemia, multiple myeloma, pediatric cancers, and head and neck cancers. Additionally, Cellectar Biosciences is developing CLR 1900, a PDC chemotherapeutic program for solid tumors, and has collaborative PDC programs with several partners. The company generates revenue through the development and commercialization of its drug candidates for cancer therapy.

Products

• CLR 131 (iopofosine I-131)

• CLR 1900 (PDC chemotherapeutic program)

• Collaborative PDC programs